NO20006007L - Fremgangsmåte til dosering av et medikament, samt doseringsform - Google Patents

Fremgangsmåte til dosering av et medikament, samt doseringsform

Info

Publication number
NO20006007L
NO20006007L NO20006007A NO20006007A NO20006007L NO 20006007 L NO20006007 L NO 20006007L NO 20006007 A NO20006007 A NO 20006007A NO 20006007 A NO20006007 A NO 20006007A NO 20006007 L NO20006007 L NO 20006007L
Authority
NO
Norway
Prior art keywords
drug
dosing
well
dosage form
release
Prior art date
Application number
NO20006007A
Other languages
English (en)
Other versions
NO330235B1 (no
NO20006007D0 (no
Inventor
Atul Dewdatt Ayer
Carol A Christopher
Diane R Guinta
Suneel K Gupta
Lawrence Hamel
Zahedeh Hatamkhany
Andrew C Lam
Samuel R Saks
Padmaja Shivanand
Richard G Weyers
Jeri Dawn Wright
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/253,317 external-priority patent/US6919373B1/en
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20006007D0 publication Critical patent/NO20006007D0/no
Publication of NO20006007L publication Critical patent/NO20006007L/no
Publication of NO330235B1 publication Critical patent/NO330235B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/88—Investigating the presence of flaws or contamination
    • G01N21/95—Investigating the presence of flaws or contamination characterised by the material or shape of the object to be examined
    • G01N21/9508—Capsules; Tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20006007A 1998-06-03 2000-11-28 Doseringsform til dosering av et medikament, samt anvendelse NO330235B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8778798P 1998-06-03 1998-06-03
US09/253,317 US6919373B1 (en) 1996-11-12 1999-02-19 Methods and devices for providing prolonged drug therapy
PCT/US1999/011920 WO1999062496A1 (en) 1998-06-03 1999-05-27 Methods and devices for providing prolonged drug therapy

Publications (3)

Publication Number Publication Date
NO20006007D0 NO20006007D0 (no) 2000-11-28
NO20006007L true NO20006007L (no) 2001-02-05
NO330235B1 NO330235B1 (no) 2011-03-07

Family

ID=26777397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006007A NO330235B1 (no) 1998-06-03 2000-11-28 Doseringsform til dosering av et medikament, samt anvendelse

Country Status (16)

Country Link
EP (2) EP1083879B1 (no)
JP (1) JP2002516848A (no)
KR (1) KR20080083074A (no)
CN (1) CN1209098C (no)
AT (1) ATE277594T1 (no)
AU (1) AU4319799A (no)
CA (1) CA2333688A1 (no)
DE (1) DE69920689T2 (no)
DK (1) DK1083879T3 (no)
ES (1) ES2229783T3 (no)
HK (2) HK1035492A1 (no)
IL (1) IL140020A0 (no)
NO (1) NO330235B1 (no)
NZ (1) NZ508567A (no)
PT (1) PT1083879E (no)
WO (1) WO1999062496A1 (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
WO2000025752A1 (en) * 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6702803B2 (en) * 2000-01-20 2004-03-09 Delsys Pharmaceutical Corporation Multi-step drug dosage forms
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
BR0212951A (pt) 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040092534A1 (en) * 2002-07-29 2004-05-13 Yam Nyomi V. Methods and dosage forms for controlled delivery of paliperidone
ES2355233T3 (es) * 2002-09-28 2011-03-24 Mcneil-Ppc, Inc. Formas de dosificación de liberación modificada con dos núcleos y una abertura.
GR1004330B (el) * 2002-10-14 2003-09-05 Lavipharm A.E. Φαρμακοτεχνικη μορφη για τη χορηγηση οργανικων νιτρικων ενωσεων
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
JP2006517593A (ja) * 2003-02-11 2006-07-27 アルザ・コーポレーシヨン 投薬形態物の層形状修飾方法およびそのような修飾を受けさせた投薬形態物
NZ546148A (en) 2003-09-26 2009-05-31 Alza Corp Drug coating providing high drug loading and methods for providing the same
CA2540052C (en) 2003-10-08 2012-04-10 Mallinckrodt Inc. Methylphenidate solution and associated methods of administration and production
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US7879352B2 (en) * 2004-05-21 2011-02-01 Accu-Break Technologies, Inc. Scored pharmaceutical tablets comprising a plurality of segments
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006046114A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2009023006A2 (en) * 2006-05-08 2009-02-19 Mcneil-Ppc, Inc. Modified release dosage form
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
FR2899476B1 (fr) * 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
CN102238946B (zh) * 2008-11-07 2014-11-26 株式会社三养生物制药 用于哌醋甲酯的控制释放的药物组合物
CA2780347A1 (en) 2009-12-07 2011-06-16 Mcneil-Ppc, Inc. Partial dip coating of dosage forms for modified release
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US9707217B1 (en) 2017-02-03 2017-07-18 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11547670B2 (en) 2019-03-05 2023-01-10 Amneal Complex Products Research Llc Delayed release methylphenidate compositions
CN114681422B (zh) * 2020-12-30 2023-09-05 深圳翰宇药业股份有限公司 一种硝苯地平控释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
JP2977907B2 (ja) * 1994-05-06 1999-11-15 ファイザー・インコーポレーテッド アジスロマイシンの放出調節された剤形
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
WO1998006380A2 (en) * 1996-08-16 1998-02-19 Alza Corporation Dosage form for providing ascending dose of drug
PT932388E (pt) * 1996-09-30 2006-07-31 Alza Corp Forma de dosagem e metodo para administracao de farmacos

Also Published As

Publication number Publication date
NO330235B1 (no) 2011-03-07
IL140020A0 (en) 2002-02-10
DE69920689T2 (de) 2005-02-24
DK1083879T3 (da) 2005-01-31
CA2333688A1 (en) 1999-12-09
EP1083879A1 (en) 2001-03-21
WO1999062496A1 (en) 1999-12-09
CN1352549A (zh) 2002-06-05
ES2229783T3 (es) 2005-04-16
JP2002516848A (ja) 2002-06-11
ATE277594T1 (de) 2004-10-15
PT1083879E (pt) 2005-01-31
DE69920689D1 (de) 2004-11-04
HK1046638A1 (en) 2003-01-24
HK1046638B (zh) 2006-02-24
CN1209098C (zh) 2005-07-06
HK1035492A1 (en) 2001-11-30
NO20006007D0 (no) 2000-11-28
KR20080083074A (ko) 2008-09-12
NZ508567A (en) 2004-02-27
EP1083879B1 (en) 2004-09-29
EP1449524A1 (en) 2004-08-25
AU4319799A (en) 1999-12-20

Similar Documents

Publication Publication Date Title
NO20006007L (no) Fremgangsmåte til dosering av et medikament, samt doseringsform
DK1001772T3 (da) Forbedret afgivelse af flere doser af et medikament
ATE359077T1 (de) Orale gabe von 6-hydroxy-oxymorphon als analgetikum
HRP20041152B1 (en) Pharmaceutical formulations
ATE274902T1 (de) Pharmazeutische dosierungsformen zur kontrollierter pulsierender abgabe
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
NO20053224D0 (no) Patient controlled drug administration device.
HK1100166A1 (en) Effervescent oral opiate dosage form
HUP0101017A2 (hu) Készítmény és eljárás szájon át adagolható vakcinák és gyógyászati hatóanyagok szisztémás bevitelére
CY1112260T1 (el) Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης
DK0841903T3 (da) Orale farmaceutiske præparater indeholdende antimikrobielt virksomme aktivstoffer og sustained release pantoprazol
NO971206D0 (no) Forlenget-frigjöringsformulering
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
DE60324427D1 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
ATE325606T1 (de) Dosisform mit ansteigender dosisfreisetzung
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
DE60207951D1 (de) Pharmazeutische Formulierungen von Thyroidhormonen
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
NO20025394D0 (no) Formuleringer inneholdende et glukokorticoid legemiddel for behandling av bronkopulmonire sykdommer
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
NO20002526D0 (no) Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav
NO971574D0 (no) Medisinmateanordning for tildeling av medisin via munnen særlig beregnet for mindre barn
GB0201607D0 (en) Formulation for the administration of medicinal substances

Legal Events

Date Code Title Description
MK1K Patent expired